The Oncology Institute, Inc.— Sankey Diagram
Quarterly mode · period ending 2025-12-31 · SEC EDGAR
ComparingFY2025 (Q4) vs FY2024 (Q4)
Revenue
$142M
↑+41.6% +$42Mvs FY2024 (Q4)
Gross Profit
$142M
↑+41.6% +$42Mvs FY2024 (Q4)
Operating Income
$112M
↑+52.4% +$39Mvs FY2024 (Q4)
Net Income
$110M
↑+52.2% +$38Mvs FY2024 (Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 (Q4) | FY2024 (Q4) |
|---|---|---|
| Revenue | $142M | $100M |
| COGS | $0 | $0 |
| Gross Profit | $142M | $100M |
| R&D | $0 | $0 |
| SG&A | $28M | $25M |
| D&A | $2M | $2M |
| Other OpEx | $0 | $0 |
| Operating Income | $112M | $74M |
| Interest Exp. | $2M | $1M |
| Other Non-Op | $0 | $0 |
| Pretax Income | $110M | $73M |
| Tax | $0 | $0 |
| Net Income | $110M | $73M |
QuarterCharts · SEC EDGAR data · DFPH · Comparing FY2025 (Q4) vs FY2024 (Q4)